Also found in: Dictionary, Wikipedia.


(ser-ta-kon-a-zole) ,


(trade name)


Therapeutic: antifungals
Pharmacologic: imidazoles


Topical treatment of interdigital tinea pedis in immunocompetent patients.


Inhibits synthesis of ergosterol, a component of fungal cell membrane, resulting in cytoplasmic leakage and fungal cell death.

Therapeutic effects

Resolution of fungal infection.
Active against Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum.


Absorption: Minimal systemic absorption.
Distribution: Unknown.
Metabolism and Excretion: Unknown.
Half-life: Unknown.

Time/action profile

topwithin 2 wkunknownunknown


Contraindicated in: Hypersensitivity to sertaconazole or other imidazoles.
Use Cautiously in: Obstetric: Use only if clearly needed; Lactation / Pediatric: Lactation and children <12 yr (safety not established).

Adverse Reactions/Side Effects


  • application site reactions
  • burning
  • contact dermatitis
  • dry skin
  • tenderness


Drug-Drug interaction

None noted.


Topical (Adults and Children >12 yr) Apply twice daily for 4 wk.


Cream: 2%

Nursing implications

Nursing assessment

  • Inspect involved areas of skin and mucous membranes before and frequently during therapy. Increased skin irritation may indicate need to discontinue medication.

Potential Nursing Diagnoses

Impaired skin integrity (Indications)
Risk for infection (Indications)


  • Topical: Apply small amount to cover affected areas between the toes and the immediately surrounding healthy skin. Dry affected area well if applied after bathing. Avoid the use of occlusive wrappings or dressings unless directed by health care professional.

Patient/Family Teaching

  • Instruct patient to apply medication as directed for full course of therapy, even if symptoms have improved. Emphasize the importance of avoiding the eyes, nose, mouth, and other mucous membranes. Do not use for disorders other than for which it was prescribed.
  • Patients with athlete’s foot should be taught to wear well-fitting, ventilated shoes and to change shoes and socks at least once a day.
  • Advise patient to report increased skin irritation, redness, itching, burning, blistering, swelling, oozing, or lack of response to therapy to health care professional.

Evaluation/Desired Outcomes

  • Decrease in skin irritation and resolution of infection. If no clinical improvement is seen in 2 wk, diagnosis should be reviewed. Recurrent fungal infections may be a sign of systemic illness.
References in periodicals archive ?
We came across less number of trials reported in literature comparing efficacy, safety and cost-effectiveness of topical antifungals clotrimazole and sertaconazole in the treatment of tinea corporis/cruris.
One group was treated with topical clotrimazole 1% cream while other received topical sertaconazole 2% cream.
Out of 60 patients enrolled in the study (30 in each group), 1 patient from clotrimazole group and 3 patients from sertaconazole group were lost to follow-up and 56 patients completed the study.
Among 110 patients that were fulfilling the criteria 55 were treated with 2% sertaconazole cream and 55 with 1% clotrimazole cream.
Out of 110 patients, 100 (51 patients sertaconazole and 49 patients clotrimazole) completed treatment course.
7%) for sertaconazole and clotrimazole groups respectively.
This increase was primarily the result of sales of Amnesteem(TM) which was launched in the third quarter of fiscal 2003, as well as the sertaconazole sale.
and Canadian rights for sertaconazole to the Ortho Neutrogena Division of Ortho-McNeil Pharmaceutical Inc.
This press release includes statements that constitute "forward-looking statements," including with regard to the payment to be made to the Company and the marketing of sertaconazole.
The sale of Sertaconazole to Ortho Neutrogena is another step taken by Mylan to rationalize and position our branded portfolio for the future," stated Robert J.
Sertaconazole is an imidazole derivative antifungal that will be indicated for the treatment of Tinea Pedis.
This press release includes statements that constitute "forward-looking statements," including with regard to the FDA approval of Sertaconazole and the payment to the Company contingent on such approval, and with regard to the Company's branded portfolio including the positioning of Mentax.